Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 33fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Rituximab 14Tacrolimus 13Busulfan 12Vincristine 11Prednisone 11Methotrexate 11Filgrastim 11Doxorubicin 11Cyclosporine 11Radiotherapy 10Brentuximab Vedotin 10Antilymphocyte Serum 10Methylprednisolone 8Cytarabine 8Melphalan 7Cisplatin 6Ifosfamide 5Gemcitabine 5merphos 4ibritumomab tiuxetan 4Sirolimus 4Flow Cytometry 4Dexamethasone 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large-Cell, Anaplastic × Comparative Genomic Hybridization × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡